Amy Freyman

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer

Lecia V. Sequist, Benjamin Besse, Thomas J. Lynch et al. · Journal of Clinical Oncology · 2010 · 426 citations · Full text

Medicine, Oncology, Pharmacology +16

Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial

Brett King, Xingqi Zhang, Walter Gubelin Harcha et al. · The Lancet · 2023 · 261 citations · Full text

Medicine, Dermatology, Pharmacology +7

Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer

Louis WC Chow, Binghe Xu, Sudeep Gupta et al. · British Journal of Cancer · 2013 · 84 citations · Full text

Medicine, Oncology, Pharmacology +16

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study

Mark D. Pegram, Igor Bondarenko, Marina Moreira Costa Zorzetto et al. · British Journal of Cancer · 2018 · 60 citations · Full text

Medicine, Oncology, Pharmacology +15

A randomized, double-blind study of PF-05280014 (a potential trastuzumab biosimilar) vs trastuzumab, both in combination with paclitaxel, as first-line treatment for HER2-positive metastatic breast cancer

Mark D. Pegram, Elizabeth Tan-Chiu, Amy Freyman et al. · Annals of Oncology · 2017 · 19 citations · Full text

Medicine, Oncology, Pharmacology +17